Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vyriad, Inc.
Raquel Deering, one of In Vivo's 2020 Rising Leaders, discusses Regeneron's efforts to develop combination therapies, its collaborations with cancer vaccine companies, and its plans to become a major force in the oncology field.
AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.
Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014-January 2015.
- Large Molecule
- Other Names / Subsidiaries
- Omnis Pharmaceuticals, Inc.
- Magnis Therapeutics, LLC.